European urology oncology最新文献

{"title":"VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification","authors":"Ailin Dehghanpour,&nbsp;Martina Pecoraro,&nbsp;Gu-mu-yang Zhang,&nbsp;Antonella Borrelli,&nbsp;Ludovica Laschena,&nbsp;Francesca Mezzapesa,&nbsp;Riccardo Mastroianni,&nbsp;Emanuele Messina,&nbsp;Fabio Massimo Magliocca,&nbsp;Giuseppe Simone,&nbsp;Valeria Panebianco","doi":"10.1016/j.euo.2026.05.012","DOIUrl":"10.1016/j.euo.2026.05.012","url":null,"abstract":"<div><h3>Background</h3><div>The Vesical Imaging-Reporting and Data System (VI-RADS) was introduced to standardize bladder magnetic resonance imaging (MRI) interpretation, mainly in treatment-naïve patients. However, most patients undergo MRI after transurethral resection of bladder tumor (TURBT), where postprocedural changes compromise diagnostic accuracy. This study aimed to identify the dominant sequence for post-TURBT VI-RADS scoring, define optimal MRI timing, and evaluate the effect of image quality.</div></div><div><h3>Methods</h3><div>This retrospective single-center study included patients with bladder cancer who underwent TURBT followed by MRI. Three radiologists assigned standard, diffusion-weighted imaging (DWI)-dominant, and dynamic contrast-enhanced (DCE)-dominant VI-RADS scores using a cutoff of ≥3. Histopathology from re-TURBT or cystectomy served as the reference standard. Diagnostic performance was assessed with receiver operating characteristic analysis and stratified by time interval (&lt;2 wk, 2–4 wk, &gt;4 wk) and VI-RADS Quality Score (QS). Inter-reader agreement was evaluated using pairwise Cohen’s κ and overall Fleiss’ κ.</div></div><div><h3>Results</h3><div>The final cohort comprised 123 patients. Standard and DCE-dominant VI-RADS produced identical results (area under the curve [AUC] = 0.81; sensitivity = 95%; specificity = 67%; accuracy = 77%). For DWI-dominant VI-RADS, AUC ranged from 0.86 to 0.95 and accuracy from 86% to 96% across readers. Inter-reader agreement was excellent (overall Fleiss’ κ = 0.91–0.96; pairwise Cohen’s κ = up to 0.98). Diagnostic accuracy varied by time interval, reaching its lowest within 2 wk (specificity = 13%, accuracy = 26%) and improving at 2–4 wk (accuracy = 94–98%). Accuracy also improved with increasing QS. The study is limited by its retrospective design and single-center setting.</div></div><div><h3>Conclusion</h3><div>Bladder MRI after TURBT remains accurate when timing, sequence weighting, and image quality are considered. DWI-dominant VI-RADS shows numerically higher diagnostic estimates. Scheduling MRI ≥2–4 wk after TURBT and ensuring adequate image quality may improve reliability.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Pages 930-937"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agentic AI for Prostate Cancer: A Vision for Multimodal Clinical Intelligence","authors":"N. Papanikolaou,&nbsp;A.R. Padhani,&nbsp;F. Sanguedolce","doi":"10.1016/j.euo.2026.03.016","DOIUrl":"10.1016/j.euo.2026.03.016","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Pages 1005-1007"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Develtere D, Devos G. Metformin in prostate cancer: A negative repurposing story across the disease continuum. Urol Oncol 2026. https://doi.org/10.1016/j.euo.2026.04.014.","authors":"Cameron E. Alexander,&nbsp;Ashwin Sachdeva,&nbsp;Noel W. Clarke","doi":"10.1016/j.euo.2026.05.020","DOIUrl":"10.1016/j.euo.2026.05.020","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Pages 1018-1019"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148360267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hall of Fame","authors":"","doi":"10.1016/S2588-9311(26)00224-5","DOIUrl":"10.1016/S2588-9311(26)00224-5","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Page viii"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148859506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry","authors":"Idir Ouzaid,&nbsp;Pierre Bigot,&nbsp;Morgan Rouprêt","doi":"10.1016/j.euo.2026.06.010","DOIUrl":"10.1016/j.euo.2026.06.010","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Pages 1008-1009"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma","authors":"Chris Ho-Ming Wong,&nbsp;David Ka-Wai Leung,&nbsp;Ivan Ching-Ho Ko,&nbsp;Brian Siu,&nbsp;Yuhong Yuan,&nbsp;Jeremy Yuen-Chun Teoh","doi":"10.1016/j.euo.2025.09.002","DOIUrl":"10.1016/j.euo.2025.09.002","url":null,"abstract":"<div><h3>Background and objective</h3><div>Radical nephroureterectomy is the standard of care for management of upper tract urothelial carcinoma (UTUC), but treatment-associated morbidity is not uncommon. Intracavitary therapy has emerged as a less invasive alternative for selected cases, particularly carcinoma in situ (CIS) and low-grade papillary tumors. We conducted a systematic review to evaluate the outcomes, recurrence rates, and adverse events associated with intracavitary therapy (immunotherapy or chemoablation) for UTUC.</div></div><div><h3>Methods</h3><div>The review protocol was registered on PROSPERO and adhered to PRISMA guidelines. The MEDLINE, Embase, and Cochrane databases were searched in October 2024 using terms related to UTUC and intraluminal therapy. Both randomized and nonrandomized studies and single-arm studies were included.</div></div><div><h3>Key findings and limitations</h3><div>We included 11 articles reporting on nine unique studies (368 patients in total) in the review. Four studies were in upper tract CIS and five were in papillary UTUC. For CIS, Bacillus Calmette-Guérin immunotherapy resulted in a CR rate ranging from 72.7% to 100%, and a 12-mo persistent response rate of 63.6–80%. For gemcitabine-docetaxel instillation in upper-tract CIS, the recurrence-free survival rate at 12 mo was 78%. For papillary UTUC, chemoablation with mitomycin gel (UGN-101) achieved CR rates of 36.4–57.7%, with 12-mo recurrence-free survival rates ranging from 13.6% to 53.1%. Adverse events included ureteric stricture (4.5–10%), hematuria (3.1–32.8%), and loin pain (18.8–34.4%).</div></div><div><h3>Conclusions and clinical implications</h3><div>Intracavitary therapy for UTUC in the form of BCG for CIS and mitomycin C for papillary disease shows considerable efficacy, with acceptable safety profiles. These therapies represent a renal-preserving alternative for patients unfit for surgery or at high risk of renal failure, and the evidence supports their use in carefully selected patients.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Pages 967-976"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why Renal Cancer Guidelines Should be Tailored to Histologic Subtype","authors":"Andrea Pettit,&nbsp;Ali J. Hajiran,&nbsp;Steven C. Campbell","doi":"10.1016/j.euo.2026.05.001","DOIUrl":"10.1016/j.euo.2026.05.001","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Pages 746-749"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148224081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PROTEUS Trial the Day After: Practice Changing or Premature Escalation?","authors":"Isabel Heidegger,&nbsp;Chiara Mercinelli,&nbsp;Giulia Marvaso,&nbsp;Jean Cristophe Bernhard,&nbsp;Elena Castro,&nbsp;Tamás Fazekas,&nbsp;Giorgio Gandaglia,&nbsp;Juan Gomez-Rivas,&nbsp;Guillaume Ploussard,&nbsp;Maria Rosaria Raspollini,&nbsp;Lara Rodriguez-Sanchez,&nbsp;Francesco Sanguedolce,&nbsp;Roderick van den Bergh,&nbsp;Morgan Rouprêt,&nbsp;Alessandro Volpe,&nbsp;Gianluca Giannarini,&nbsp;Pierre Blanchard,&nbsp;EAU Oncology Section Prostate Cancer Working Group","doi":"10.1016/j.euo.2026.06.009","DOIUrl":"10.1016/j.euo.2026.06.009","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Pages 752-755"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Patients with Metastatic Non–clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","authors":"Kosuke Takemura,&nbsp;Jeffrey Graham,&nbsp;David Maj,&nbsp;Martin Zarba,&nbsp;J. Connor Wells,&nbsp;Razane El Hajj Chehade,&nbsp;Marc Eid,&nbsp;Eddy Saad,&nbsp;Renee Maria Saliby,&nbsp;Jae-Lyun Lee,&nbsp;Frede Donskov,&nbsp;Benoit Beuselinck,&nbsp;Evon Jude,&nbsp;Rana R. McKay,&nbsp;Naveen S. Basappa,&nbsp;Sumanta K. Pal,&nbsp;Camillo Porta,&nbsp;Neeraj Agarwal,&nbsp;Toni K. Choueiri,&nbsp;Daniel Y.C. Heng","doi":"10.1016/j.euo.2025.12.018","DOIUrl":"10.1016/j.euo.2025.12.018","url":null,"abstract":"<div><h3>Background and objective</h3><div>Real-world evidence on the effectiveness of first-line immuno-oncology (IO)-based combinations or cabozantinib (CABO) over traditional targeted therapies in metastatic non–clear cell renal cell carcinoma (nccRCC) is limited. This study aims to compare the outcomes of first-line therapies for metastatic nccRCC according to histologic subtypes, including papillary renal cell carcinoma (RCC), unclassified RCC, and chromophobe RCC with or without sarcomatoid dedifferentiation.</div></div><div><h3>Methods</h3><div>Using the International Metastatic Renal Cell Carcinoma Database Consortium, patients with metastatic nccRCC who received (1) IO plus vascular endothelial growth factor (IOVE) combination therapy, (2) IOIO doublet therapy, (3) CABO monotherapy, (4) sunitinib or pazopanib (SUN/PAZ) monotherapy, or (5) mammalian target of rapamycin (mTOR) monotherapy were included. Baseline patient characteristics, clinician assessment of objective response rates (ORRs), and overall survival (OS) were compared across first-line therapy regimens.</div></div><div><h3>Key findings and limitations</h3><div>The most common nccRCC histology was papillary found in 725 (47%), and sarcomatoid dedifferentiation was found in 236 (15%) of the 1551 patients included. Within the papillary RCC cohort, ORRs and median OS were, respectively, 31% and 33.2 mo for IOVE, 26% and 31.9 mo for IOIO, and 37% and 30.7 mo for CABO, as compared with 13% and 17.2 mo for SUN/PAZ and 3.4% and 13.1 mo for mTOR. Within the sarcomatoid dedifferentiation cohort, receipt of IOIO was associated with the highest ORR and the longest median OS (39% and 31.9 mo, respectively).</div></div><div><h3>Conclusions and clinical implications</h3><div>Distinct patient outcomes were observed across histologic subtypes. More histology-specific strategies are required given the differential activity of first-line therapy regimens against each nccRCC histology.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Pages 786-794"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy Escalation in BCG-Naïve NMIBC: Time for Selectivity, Not Enthusiasm","authors":"Marco Moschini,&nbsp;Maria Carmen Mir,&nbsp;Jonathan Aning,&nbsp;Alessandro Volpe,&nbsp;EAU Oncology Section","doi":"10.1016/j.euo.2026.03.020","DOIUrl":"10.1016/j.euo.2026.03.020","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"9 4","pages":"Pages 741-742"},"PeriodicalIF":8.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}